Brain Genome - Pharmacogenomics Education Platform

    Cardiovascular Medication+ Genetics Report

    Understand what years of pharmacogenomics research may reveal about YOUR response to 30+ cardiovascular medications including statins, blood thinners, beta-blockers, and antiarrhythmics.

    $19.95
    Educational report — not a clinical test
    DNA Never Leaves Your Browser
    Instant Results

    Why Genetics Matter for Heart Medications

    Cardiovascular medications have some of the strongest evidence in medicine. Your genetics can significantly affect how you respond.

    FDA Boxed Warnings

    Clopidogrel (Plavix) carries an FDA boxed warning about CYP2C19 poor metabolizers who may not adequately activate the drug, potentially leaving them at risk for cardiovascular events

    CPIC Level A Guidelines

    Warfarin and clopidogrel have the highest level of pharmacogenomic evidence with CPIC Level A clinical guidelines recommending genotype-guided dosing

    Statin Muscle Risk

    SLCO1B1 gene variants are linked to statin-associated muscle symptoms. Research shows SLCO1B1*5 carriers have increased risk of myopathy with certain statins

    8 Medication Categories Covered

    Your report covers 30+ cardiovascular medications organized across these therapeutic categories

    Anticoagulants

    Blood thinners like warfarin, apixaban, rivaroxaban

    Warfarin has CPIC Level A guidelines for CYP2C9/VKORC1

    Antiplatelets

    Clopidogrel, prasugrel, ticagrelor

    Clopidogrel has an FDA boxed warning for CYP2C19 poor metabolizers

    Statins

    Atorvastatin, simvastatin, rosuvastatin, pravastatin

    SLCO1B1 variants linked to statin-related muscle side effects

    Beta-Blockers

    Metoprolol, carvedilol, propranolol, atenolol

    CYP2D6 metabolizer status affects metoprolol levels

    Antiarrhythmics

    Amiodarone, flecainide, propafenone

    CYP2D6 status impacts flecainide and propafenone metabolism

    ACE Inhibitors/ARBs

    Lisinopril, losartan, valsartan, enalapril

    Losartan is a prodrug activated by CYP2C9

    Calcium Channel Blockers

    Amlodipine, diltiazem, verapamil, nifedipine

    CYP3A4 metabolism affects several CCBs

    Other Cardiovascular

    Digoxin, hydralazine, ranolazine, and more

    NAT2 status affects hydralazine metabolism

    Report Preview

    What You'll See for Every Medication

    Each medication in your report gets a complete, personalized analysis. Click any section below to see a preview using Clopidogrel as an example.

    Report Sections

    Clopidogrel(Plavix)
    Antiplatelet
    Tier 1

    About Clopidogrel

    Antiplatelet medication used to prevent blood clots after heart attack, stroke, or in patients with peripheral artery disease.

    Drug Class

    Antiplatelet

    Brand Names

    Plavix

    Mechanism

    Platelet P2Y12 receptor inhibition

    Evidence Level

    CPIC Level A
    CPIC Guidelines FDA Labels PharmGKB
    Based on published research

    Key Genes We Analyze

    These genes have the strongest evidence for cardiovascular medication response

    CYP2C19

    CPIC Level A

    Clopidogrel activation, some proton pump inhibitors

    CYP2C9

    CPIC Level A

    Warfarin metabolism, losartan activation, NSAID metabolism

    VKORC1

    CPIC Level A

    Warfarin sensitivity target

    SLCO1B1

    CPIC Level A

    Statin hepatic uptake transporter

    CYP2D6

    CPIC Level A

    Metoprolol, propranolol, flecainide metabolism

    CYP3A4/5

    PharmGKB/FDA

    Calcium channel blockers, some statins, amiodarone

    How It Works

    1

    Upload Your DNA

    Upload your raw DNA data from 23andMe, AncestryDNA, or other consumer tests. Your full file is processed locally -- it never leaves your browser.

    2

    Instant Analysis

    We match your genetic variants against published research from CPIC, PharmGKB, FDA labels, and peer-reviewed studies on cardiovascular medications.

    3

    Your Personalized Report

    Get a detailed report showing how your genetics may affect response to 30+ cardiovascular medications, with evidence tiers and research citations.

    Best Value

    Get All 3 Reports for $49.95

    Mental Health + Cardiovascular + Pain — $59.85 Save $9.90

    Also Available

    Explore our other pharmacogenomics reports

    Mental Health Report

    49+ psychiatric medications — SSRIs, SNRIs, antipsychotics, mood stabilizers, ADHD meds

    Pain Report

    29 pain medications — opioids, NSAIDs, muscle relaxants, migraine treatments

    Frequently Asked Questions

    Is this a diagnostic test or medical advice?
    No. This is not a medical device, diagnostic test, or clinical service. This is an educational report that summarizes published pharmacogenomic research as it may relate to your genetic variants. It is not FDA-approved or clinically validated. Always consult a qualified healthcare provider before making any medication decisions.
    What DNA tests are compatible?
    Our report works with raw DNA data from 23andMe, AncestryDNA, MyHeritage, FamilyTreeDNA, Living DNA, and most other consumer genetic testing services.
    How is my genetic data protected?
    Your complete DNA file is processed locally in your browser -- your full genetic file is never uploaded to our servers. We extract and store only the specific genetic variants (~1,000 SNPs) needed for pharmacogenomic analysis. We never sell or share your genetic information with third parties.
    Which cardiovascular medications are covered?
    The report covers 30+ cardiovascular medications across 8 categories: anticoagulants (warfarin, apixaban), antiplatelets (clopidogrel, prasugrel), statins (atorvastatin, simvastatin, rosuvastatin), beta-blockers (metoprolol, carvedilol), antiarrhythmics (amiodarone, flecainide), ACE inhibitors/ARBs, calcium channel blockers, and other cardiovascular drugs.
    Why is pharmacogenomics important for heart medications?
    Some cardiovascular medications have strong pharmacogenomic evidence. For example, CYP2C19 status affects clopidogrel activation (FDA boxed warning), CYP2C9 and VKORC1 variants affect warfarin dosing (CPIC Level A guidelines), and SLCO1B1 variants affect statin-related muscle side effects. Understanding your genetics can help your healthcare provider make more informed prescribing decisions.
    Can I share this report with my cardiologist?
    Yes, you may share this report with your healthcare provider as a conversation starter. The report includes research citations that providers can review. This report is educational and does not replace clinical pharmacogenomic testing.
    How is this different from clinical pharmacogenomic testing?
    This is not a substitute for clinical pharmacogenomic testing. Clinical tests are performed in CLIA-certified labs with validated methodologies. Our educational report uses consumer DNA data to help you understand published research.
    What are the limitations of this report?
    Important limitations include: consumer DNA tests may not detect all clinically relevant variants; pharmacogenomics is only one factor in medication response; cardiovascular medications require careful clinical monitoring; this report is not FDA-approved or clinically validated; never adjust heart medications without consulting your healthcare provider.

    Ready to Understand Your Cardiovascular Genetics?

    Get personalized, research-backed insights about how your genetics may affect response to 30+ cardiovascular medications. One-time purchase, instant access, lifetime updates.

    $19.95
    Preview Sample Report

    Disclaimer: This report is for educational and informational purposes only. It is not a medical device, diagnostic test, or clinical pharmacogenomic service. This report is not FDA-approved or clinically validated. All information is derived from publicly available research and should not be used as a substitute for professional medical consultation.

    Cardiovascular medications require careful monitoring by your healthcare provider. Never adjust, discontinue, or start any heart medication based on this report alone. Always consult your cardiologist or prescribing physician before making any changes to your cardiovascular medication regimen.